ONEVAX, LLC
Biotech · Acquired
In vivo tolerogenic vaccine (OV-01) using dendritic cells to induce immune tolerance in autoimmune diseases
- Grants
- $2.5M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20162017201820192020
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · A novel biomaterial-based therapy utilizing auto-antigen and adjuvant for the amelioration of Type 1 Diabetes | $238,328 | |
| Federal grant | Department of Health and Human Services · Phase I · A novel biomaterial based therapy utilizing auto antigen and adjuvant for the amelioration of Type Diabetes | $238,328 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Biomaterial based delivery of Interleukin to Regulatory T Cells for the amelioration of Type Diabetes | $235,720 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Biomaterial-based delivery of Interleukin-2 to Regulatory T Cells for the amelioration of Type 1 Diabetes | $235,720 | |
| Federal grant | Department of Health and Human Services · Phase I · Therapeutic Administration of Suppressor of Cytokine Signaling Mimetics to Ameliorate Type 1 Diabetes | $117,817 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a dual microparticle platform vaccine system encapsulating immunomodulatory agents and antigen for the amelioration of type 1 diabetes | $221,331 | |
| Federal grant | Department of Health and Human Services · Phase I · Biomaterial-Based Delivery of Suppressor of Cytokine Signaling Mimetics to Ameliorate Type 1 Diabetes | $195,808 | |
| Federal grant | Department of Health and Human Services · Phase II · A polymeric biomaterial-based vaccine utilizing immunomodulatory agents and antigen for the amelioration of type 1 diabetes. | $989,307 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1701 | Purespring Therapeutics | — | — |
| 1702 | TEGA THERAPEUTICS INC | — | — |
| 1703 | BIOSPUTNIK LLC | — | — |
| 1704 | ONEVAX, LLC | — | — |
| 1705 | Prokaryotics, Inc. | — | — |
| 1706 | Phoenix Nest Inc. | — | — |
| 1707 | Remedy Labs, Inc. | — | $500K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.